Delivery Order SPE2DB22D2206-SPE2DB23FHE17
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution company. The $9,863.79 firm fixed price delivery order is for the supply of INFUVITE ADULT VIAL 10ML, a pharmaceutical product, with a completion date of March 18, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract (IDC) with DLA with a potential value of...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,126.15 Firm Fixed Price delivery order contract is for the supply of INFUVITE ADULT VIAL 10ML medical products. The contract has an ultimate completion date of May 2, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,499.73 firm fixed-price delivery order is for the supply of Infuvite Adult Vial 10ML, a pharmaceutical product. The contract has an ultimate completion date of July 17, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award is for the delivery of medical supplies, specifically INFUVITE ADULT VIAL 10ML, to the Defense Logistics Agency (DLA) by the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,070.94 firm fixed-price delivery order contract runs through November 15, 2023 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,999.46 firm fixed-price delivery order is for the supply of 4568250414 - INFUVITE ADULT VIAL 10ML, with a performance period through May 15, 2025. The contract is not set-aside and represents open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award, valued at $1,499.73, is for the delivery of INFUVITE ADULT VIAL 10ML medical supplies. This is a Firm Fixed Price Delivery Order contract that runs through April 4, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of INFUVITE ADULT BULK VIAL 100ML pharmaceutical products. The $29,529.66 firm fixed price contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of June 21, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds two Indefinite Delivery Contracts (IDCs) with the DLA and Department of Justice Federal Bureau of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,000.10 firm fixed-price delivery order is for the supply of INFUVITE ADULT VIAL 10ML, a medical product, with a completion date of May 16, 2025. The contract is not set aside and represents an individual delivery order under Amerisourcebergen's broader $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
- This is a $12,655.78 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of INFUVITE ADULT VIAL 10ML medical products, with a completion date of May 14, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award, valued at $2,529.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of INFUVITE PEDIATRIC VIAL 5ML medical supplies, with a completion date of March 18, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB23FHE17Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $59,659.19 firm fixed-price delivery order is for the supply of INFUVITE ADULT VIAL 10ML medical products, with a performance period ending on May 16, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This single-award IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract award reviewed was not designated with any set-aside requirements, indicating open competition. Amerisourcebergen's parent company, Cencora, Inc., also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.7k | 5/15/23 |